Hedge Fund’s $621 Million Invested in Healthcare Stocks: CEPH, JNJ, PFE

Wall St. Watchdog reveals information regarding Gabelli Funds’ top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 93 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $621.628 million.

  • Cephalon Inc. (NASDAQ:CEPH): On 06/30/2011, Gabelli Funds reported holding 671,000 shares with a market value of $53,612,901. This comprised 0.36% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 657,000 shares with a market value of $53,019,898. This comprised 0.43% of the total portfolio. The net change in shares for this position over the two quarters is -14,000. About Company: Cephalon, Inc. is an international biopharmaceutical company that discovers, develops, and markets biopharmaceutical products to treat neurological disorders, pain, and cancer. The Company’s products include a product that treats excessive daytime sleepiness associated with narcolepsy.
  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Gabelli Funds reported holding 721,500 shares with a market value of $47,994,178. This comprised 0.32% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 767,500 shares with a market value of $48,882,074. This comprised 0.39% of the total portfolio. The net change in shares for this position over the two quarters is 46,000. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Gabelli Funds reported holding 2,280,790 shares with a market value of $46,984,275. This comprised 0.32% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 2,269,790 shares with a market value of $40,129,888. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is -11,000. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Gabelli Funds reported holding 1,139,987 shares with a market value of $33,014,022. This comprised 0.22% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 1,148,987 shares with a market value of $36,055,211. This comprised 0.29% of the total portfolio. The net change in shares for this position over the two quarters is 9,000. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Gabelli Funds reported holding 1,014,650 shares with a market value of $35,806,999. This comprised 0.24% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 1,073,650 shares with a market value of $35,108,356. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is 59,000. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Covidien Plc (NYSE:COV): On 06/30/2011, Gabelli Funds reported holding 573,500 shares with a market value of $30,527,405. This comprised 0.21% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 573,500 shares with a market value of $25,291,349. This comprised 0.2% of the total portfolio. The net change in shares for this position over the two quarters is 0. About Company: Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Gabelli Funds reported holding 674,000 shares with a market value of $25,295,219. This comprised 0.17% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 675,000 shares with a market value of $24,954,751. This comprised 0.2% of the total portfolio. The net change in shares for this position over the two quarters is 1,000. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Becton Dickinson And Company (NYSE:BDX): On 06/30/2011, Gabelli Funds reported holding 323,200 shares with a market value of $27,850,143. This comprised 0.19% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 330,700 shares with a market value of $24,246,924. This comprised 0.2% of the total portfolio. The net change in shares for this position over the two quarters is 7,500. About Company: Becton, Dickinson and Company manufactures and sells a variety of medical supplies and devices and diagnostic systems. The Company’s products are used by health care professionals, medical research institutions, and the general public. Becton’s products are marketed worldwide.
  • Novartis Ag (NYSE:NVS): On 06/30/2011, Gabelli Funds reported holding 448,000 shares with a market value of $27,377,280. This comprised 0.18% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 432,000 shares with a market value of $24,092,640. This comprised 0.19% of the total portfolio. The net change in shares for this position over the two quarters is -16,000. About Company: Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases; oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; vision, and animal health products.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Gabelli Funds reported holding 434,500 shares with a market value of $22,411,511. This comprised 0.15% of the total portfolio. On 09/30/2011, Gabelli Funds reported holding 453,500 shares with a market value of $20,915,420. This comprised 0.17% of the total portfolio. The net change in shares for this position over the two quarters is 19,000. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.

(Note: Data regarding Gabelli Funds’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>